AXEL HEALTH GROUP partners with Lillia to bring globally deployed agentic AI platform to Vietnam, advancing AI-Driven chronic condition management across Southeast Asia
Embedded Files
AXEL HEALTH GROUP today announced a strategic partnership with Lillia to introduce its globally deployed agentic AI health platform to Vietnam. The collaboration aims to transform chronic condition management through AI-powered insights, clinical care pathways, and continuous patient engagement.
Lillia has already been launched in the Middle East and India, where it supports clinical teams in delivering proactive, data-driven care for chronic conditions such as diabetes. Having presented its approach to managing chronic metabolic conditions in two comprehensive ADA-published studies and multiple poster showcases at the IDF, Lillia enables clinicians to personalize treatment plans, monitor patient progress in real time, and improve long-term outcomes through sustained engagement.
Vietnam as the Launchpad for Regional Innovation
Vietnam will serve as the initial pilot market for Lillia in Southeast Asia. With chronic conditions rising rapidly and healthcare systems seeking scalable digital solutions, Vietnam offers a critical opportunity to validate and refine an integrated chronic care model tailored to local needs.
AXEL HEALTH will lead the deployment of Lillia in Vietnam, leveraging its deep regional expertise, clinical operations experience, and investment know-how to ensure successful implementation and long-term sustainability. The pilot will focus on improving care coordination, enhancing patient adherence, and reducing the burden on healthcare providers.
A Partnership Built on Complementary Strengths
The collaboration combines Lillia’s extensive capabilities in AI-driven health solutions and outcomes-based condition management models with AXEL HEALTH’s regional healthcare expertise, operational capabilities, and investment leadership. Both organizations aim to co-develop a next-generation chronic care ecosystem that is personalized, continuous, and powered by intelligent data, while scaling this model across Southeast Asia following the Vietnam pilot.
Driving the Future of Chronic Care in Asia
“By bringing Lillia to Vietnam, we are taking a major step toward reshaping how chronic diseases are managed in the region,” said Dr. Dilshaad Ali Bin Abas Ali, CEO of AXEL HEALTH GROUP. “Our partnership with DroobiSmit allows us to combine world-class digital therapeutics with local clinical insight to deliver meaningful, measurable impact.”
“After delivering measurable outcomes across chronic metabolic conditions in the Middle East and India, Lillia is now scaling into global markets, including the United States and Southeast Asia, on the back of its agentic AI platform,” said Sujit Chakrabarty, Lillia's Founder and CEO. “We are particularly excited about Southeast Asia, with Vietnam serving as a strong launchpad to demonstrate how continuous, AI-enabled care can drive meaningful outcomes at scale."
AXEL HEALTH GROUP is a regional healthcare organization focused on advancing integrated care models across Asia. With expertise spanning clinical operations, digital health deployment, and investment strategy, AXEL HEALTH partners with leading innovators to bring scalable, high-impact healthcare solutions to emerging markets.
Lillia is an agentic AI-enabled operating platform that supports the delivery of chronic care. It specializes in managing the care journey between clinic visits to ensure high adherence and compliance.
Lillia has been recognized among TIME’s World’s Top HealthTech Companies 2025. Headquartered in Singapore with Qatar designated as its GCC HQ and Global Innovation Hub, the Lillia solution has been used by 20+ healthcare organizations for efficient chronic care program execution.
Page updated
Report abuse